Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer
Open Access
- 24 March 2025
- journal article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 462-469
Abstract
Background and purpose: For the most advanced stage of metastatic castration-resistant prostate cancer (mCRPC), several life-prolonging treatments have become available over the past decade. Treatment decision-making (TDM) and experiences in this phase are yet to be studied. Hence, this study aimed to describe men’s satisfaction with TDM and treatment experiences during the first 12 months of a life-prolonging treatment of mCRPC. Patients and methods: This prospective study included 104 men with mCRPC who started and remained on the same life-prolonging treatment for 12 months. They received a questionnaire on TDM, treatment experiences, and well-being every 3 months. Correlation analyses explored associations between satisfaction with TDM at baseline and treatment experiences and well-being over time. Results and interpretation: The participants (median age: 77 years) generally reported high satisfaction with physician- and nurse communication and confidence/trust at baseline (>55% reported the highest satisfaction in all questions), but lower satisfaction with communication regarding how the treatments could affect them – up to 40% reported not having talked about that at all. Treatment experiences and physical- and emotional well-being remained stable over time. Associations were found between satisfaction with TDM at baseline and how they rated the treatment as a whole at six months, and well-being at six and 12 months. In mCRPC, men’s TDM preferences need to be explored, and shared decision-making needs to be facilitated when considering treatment. Furthermore, clinicians need to discuss how the treatment might affect patients’ everyday lives when discussing life-prolonging treatments with them.Keywords
This publication has 33 references indexed in Scilit:
- Facing life-prolonging treatment: The perspectives of men with advanced metastatic prostate cancer – An interview studyEuropean Journal of Oncology Nursing, 2020
- Unmet expectations in prostate cancer patients and their association with decision regretJournal of Cancer Survivorship, 2020
- The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onsetSupportive Care in Cancer, 2017
- Decision‐making processes among men with low‐risk prostate cancer: A survey studyPsycho-Oncology, 2017
- Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot StudyJournal of Cancer Education, 2016
- Development and validation of the functional assessment of chronic illness therapy treatment satisfaction (FACIT TS) measuresQuality of Life Research, 2013
- The relation between cancer patient treatment decision‐making roles and quality of lifeCancer, 2013
- Who makes the decision regarding the treatment of clinically localized prostate cancer–the patient or physician?Cancer, 2012
- An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32)European Journal of Cancer, 2005
- Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement systemQuality of Life Research, 1996